SGLT2i Use Linked to Reduced Cardiac Arrhythmia Risk
Sodium-glucose cotransporter 2 inhibitors use may reduce cardiac arrhythmia risk, including the risk for atrial fibrillation.
Sodium-glucose cotransporter 2 inhibitors use may reduce cardiac arrhythmia risk, including the risk for atrial fibrillation.
Researchers demonstrate the gonadotropin-releasing hormone agonist implant’s ability to control precocious puberty.
Researchers performed a systematic review of clinical practice guidelines to identify nonpharmacologic recommendations for osteoporosis treatment.
Fixed-dose bempedoic acid with ezetimibe lowered LDL-C vs placebo when added to maximally tolerated statin therapy in patients with high CVD risk and hypercholesterolemia.
Patients who attended complication screenings paid more visits to diabetes clinics within the first 2 years after diagnosis, had higher median lifetime HbA1c, and had less socioeconomic disadvantage.
Early and intensive treatment for hyperthyroidism in Graves disease is associated with improvements in cardiovascular morbidity and all-cause mortality, regardless of treatment method used.
Offering breakfast in the classroom increased the number of students participating in the subsidized school food program but also increased incidence and prevalence of obesity.
Investigators examined whether β-cell function can be improved or preserved with antihyperglycemic agents in young patients.
Investigators reviewed cases of patients with multiple sclerosis treated with alemtuzumab to determine the type and frequency of thyroid dysfunction.
Investigators revised pooled cohort equations to improve clinical accuracy to predict risk for cardiovascular disease.